Our analysts just identified a stock with the potential to be the next Nvidia. Reported revenue faced significant year-over-year headwinds due to the divestiture of non-core assets to Companion Spine and the cessation of certain license revenue following reimbursement changes. The integration of 17 new sales representatives from the Dilon distribution agreement consumed significant management resources, contributing to softer-than-expected Q2 sales performance. Management attributed biologics underperformance to softness in legacy 'workhorse' product lines and ongoing headwinds in the amniotic membrane market tied to advanced wound care. The company is transitioning from a small commercial footprint to a scaled organization with over 25 reps and expanded national accounts teams to drive institutional adoption.